LG Life Sciences shoots for the sky with W1T sales targetLG Life Sciences, a pharmaceutical manufacturer, said Monday that it will seek to reach 1 trillion won ($944.3 million) in sales by 2017 by redoubling its efforts to sell new products abroad. The company said it will strengthen sales of Zemiglo, the first-ever Korean-developed diabetes drug, at home in order to become an industry leader in drugs for disorders categorized under the umbrella term “metabolic syndrome” in Korea.
The Zemiglo pill will also hit the world market sometime this year in cooperation with Sanofi SA, a French healthcare company. Zemiglo has been approved by 79 countries including Russia and India. Biomedicine is LG Life Sciences’ other business target for the future, it said. It added that its newly-developed growth hormone for adults with growth hormone deficiency is awaiting approval by the U.S. Food and Drug Administration. LG Life Sciences expects the new growth hormone to lead its sales in the world market. Its first meningitis vaccine will enter the Chinese market later this year.
More in Economy
Tapped out and hunkered down, Korea stares recession in the face
Property owners get big tax shock
Household debt keeps climbing despite gov't efforts
Career interruptions due to marriage and childbirth down 11 percent
Despite vaccine shot in the arm, credit risk remains in markets